Chugai Seiyaku Kabushiki Kaisha

Neurmedix, Inc.

Harbor Therapeutics, Inc.

Yujin Huang

David Mark Wallace

Mi Chen

Gary David Lopaschuk

Jason Roland Dyck

Thomas Arrhenius

Alex Michael Nadzan

Steven K White

Yu Ge

Jie Fei Cheng

Lin Zhang

Sovouthy Tith

Richard Julius Penuliar

Bin Liu

Masahiro Nishimoto

Masayuki Haramura

Steve Joel Brown

Charles Stanford Harmon

Jie Fei Chang

Richard Penuliar

Gary D Lopaschuk

Jason R Dyck

The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S,10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;,7&#x3b2;,17&#x3b2;-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.

Method for preparing substituted 3,7-dihydroxy steroids

Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds-2

The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S, 10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R, 7R,17S-triol (also referred to as 17&#x3b1;-ethynyl-androst-5-ene-3&#x3b2;,7&#x3b2;,17&#x3b2;-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.

Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds

The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase. 

Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators

The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.

The present invention relates to methods for the prophylaxis, management and treatment of certain diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD) by the administration of a composition containing as an active ingredient a compound according to Formula I. In particular, the invention relates to methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the administration of a compound which inhibits malonyl-coenzyme A decarboxylase activity. The present invention also includes within its scope the novel process for the preparation of certain compounds 

Method for preparing imidazole derivatives

Growing community of inventors

San Diego, CA, United States of America

Yujin Huang